Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antihypertensive, antialbuminuric and metabolic effects of manidipine + lisinopril and manidipine, amlodipine, or telmisartan in non-diabetic hypertensive patients with metabolic syndrome

Next Previous
Trial Profile

Antihypertensive, antialbuminuric and metabolic effects of manidipine + lisinopril and manidipine, amlodipine, or telmisartan in non-diabetic hypertensive patients with metabolic syndrome

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine (Primary) ; Lisinopril (Primary) ; Manidipine (Primary) ; Telmisartan (Primary)
  • Indications Essential hypertension; Metabolic syndrome
  • Focus Pharmacodynamics
  • Acronyms MARCADOR

Most Recent Events

  • 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
  • 05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top